<DOC>
	<DOCNO>NCT00750841</DOCNO>
	<brief_summary>Phase I , open study assess effect rifampicin , market drug , body handle experimental drug cediranib patient advance cancer .</brief_summary>
	<brief_title>Study Effect Rifampicin Pharmacokinetics ( PK ) Multiple Doses Cediranib Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Written inform consent Prostate cancer ) , refractory standard therapy standard therapy exists . Estimated life expectancy least 8 week WHO performance status ( PS ) 02 . Unstable brain/meningeal metastasis Biochemistry/haematology result outside required range History significant GI impairment Inadequate bone marrow reserve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>advanced cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>rifampicin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>Advanced solid tumour</keyword>
</DOC>